How is Retatrutide administered?
This describes how Retatrutide is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once weekly schedule, generally over open-ended, titrate over 4-6 months. Specific dosing is individual and beyond general information, and human evidence for Retatrutide is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once weekly
- Cycle length: Open-ended, titrate over 4-6 months
- Half-life: ~6 days
References
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2) — Jastreboff AM et al., NEJM, 2023
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA — Rosenstock et al., Lancet, 2023
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Sanyal et al., Nature Medicine, 2024
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Retatrutide
Full Retatrutide breakdownRetatrutide what it's used forRetatrutide side effectsRetatrutide mistakes to avoidRetatrutide who should avoid itRetatrutide half-lifeRetatrutide how long to workRetatrutide legal statusRetatrutide how it workscagrilintide vs retatrutideretatrutide vs tirzepatidesemaglutide vs retatrutidevk2735 vs retatrutideAsk the AI Coach
Last updated 2026-06-15.